Drugs.com - Clinical Trials

Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain

MONMOUTH JUNCTION, NJ, March 6, 2025 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ALLEVIATE-2 Phase 3 pivotal clinical trial evaluating...

Mar 9, 2025 - 23:09
 0
Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
MONMOUTH JUNCTION, NJ, March 6, 2025 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ALLEVIATE-2 Phase 3 pivotal clinical trial evaluating...
Read More

Tags:

Previous Article

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune ...

Next Article

Hello, TELO!

Related Posts

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune Announces U.S. FDA Breakthrough Therapy Des...

Feb 9, 2025  0

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Denali Therapeutics Announces Primary Analysis and Long...

Mar 7, 2025  0

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Kura Oncology and Kyowa Kirin Announce Positive Ziftome...

Feb 9, 2025  0